Search for: "Patent Docs"
Results 381 - 400
of 1,321
Sorted by Relevance
|
Sort by Date
1 Nov 2009, 9:36 pm
By Donald Zuhn -- Over the past twelve months, Patent Docs has reported on a number of papers, letters, and statements that outline positions taken by various players in the follow-on biologics (FOB) data exclusivity debate. [read post]
29 Oct 2009, 9:59 pm
By Donald Zuhn -- Over the past twelve months, Patent Docs has reported on a number of papers, letters, and statements that outline positions taken by various players in the follow-on biologics data exclusivity debate. [read post]
28 Oct 2009, 9:59 pm
By Donald Zuhn -- Over the past twelve months, Patent Docs has reported on a number of papers, letters, and statements that outline positions taken by various players in the follow-on biologics data exclusivity debate. [read post]
2 Mar 2012, 8:28 pm
Patent Docs authors and MBHB attorneys Dr. [read post]
4 Jan 2010, 9:59 pm
By Donald Zuhn -- On New Year's Eve, we kicked off our third annual list of top biotech/pharma stories by counting down the first three of the top ten stories covered on Patent Docs in 2009 (see "Top Stories of 2009: #10, #9, and #8"). [read post]
3 Jan 2010, 9:59 pm
By Donald Zuhn -- On New Year's Eve, we kicked off our third annual list of top biotech/pharma stories by counting down the first three of the top ten stories covered on Patent Docs in 2009 (see "Top Stories of 2009: #10, #9, and #8"). [read post]
4 Sep 2008, 4:57 am
Noonan -- Earlier today, Patent Docs participated in a conference call with Jim Greenwood, the President and CEO of the Biotechnology Industry Organization (BIO) and Joshua Boger, Ph.D., Chairman of BIO's Board and President and CEO of Vertex Pharmaceuticals Inc. [read post]
2 Jul 2008, 8:23 pm
Patent Docs, discussing a letter from four Congressman to U.S. [read post]
3 Jun 2009, 9:50 pm
In that decision, issued on April 3, the Federal Circuit reversed the District Court's denial of Lilly's motion for JMOL in view of a jury verdict of infringement and validity of the asserted claims, and affirmed the District Court's ruling that Lilly failed to establish the affirmative defense of inequitable conduct (see Patent Docs report). [read post]
22 May 2009, 6:58 pm
By Donald Zuhn -- On Wednesday, we posted a report on a BIO Super Session entitled "A Model Patent Office for the Future -- Promoting and Protecting Investments in Innovation" (see "Docs at BIO: Panel Offers Suggestions for Fixing the USPTO"). [read post]
17 Jun 2011, 9:08 pm
Patent Docs author Dr. [read post]
3 Jun 2009, 9:56 pm
§ 120 (see Patent Docs report). [read post]
17 Aug 2009, 9:59 pm
Patent Docs initially reported on this study back in February, before BIO and Thomson Reuters made the report available (see "NVCA Study Shows Decline in 2008 Investment; BIO Study Predicts Biotech Rebound in 2009"). [read post]
4 Jun 2009, 9:58 pm
Doll (see Patent Docs report). [read post]
29 May 2009, 3:40 am
BlawgIT California Biotech Law Chicago IP Litigation European Patent Caselaw File Wrapper Georgia Patent Law Holman's Biotech IP Honoring the Inventor I/P Updates India Patent Intellectual Asset Management Intellectual Property Watch Inventive Step IP Estonia IP Kat IP NewsFlash IP Spotlight IP Think Tank IPJUR IPWatchdog.com Just An Examiner Nanomedicine & IP OC… [read post]
7 Jun 2011, 9:59 pm
Patent Docs intends to provide a more comprehensive analysis... [read post]
27 Jun 2008, 4:51 am
Teleflex Inc. on biopharma patent prosecution and litigation. [read post]
8 Nov 2007, 12:21 pm
[DOC] Baker, Daniel [DOC] Calvert, Ian, A. [read post]
23 Apr 2014, 6:47 pm
General Grounds for DissentToday the court expands the judicially-created doc- trine of obviousness-type double patenting. [read post]
15 Mar 2012, 10:00 pm
Suggestions include the Track One Prioritized Examination procedure, which is a new procedure at the PTO, and the Accelerated Examination program. 5) Patent Docs: A Glimpse under the Hood: How the USPTO Proposes to Adjust Patent Fees- This post explains how the USPTO has dealt with their new authority to "set or adjust by rule any fee established, authorized, or charged under title 35, United States Code, or the Trademark Act of 1946, for any services performed by or… [read post]
